Key learnings from building: A precision cancer medicine implementation initiative for Norway
Annals of Oncology(2022)
Abstract
European countries with publicly funded health care struggle with implementation of precision cancer medicine (PCM). We set out three aims in 2019: i) To establish access to advanced molecular diagnostics for stratification of patients to trials; ii) To increase the volume of trials with a PCM approach to gain experience; and iii) In parallel work for implementation of PCM into standard of care. Work proceeded along four lines: i) Sign-up to a nation-wide, bottom-up initiative with a few common priorities; ii) Aligning with top-down approaches from the Ministry and regional health care systems; iii) Exploring the possibility of a public-private partnership and iv) Coordinating with other PCM initiatives internationally. Over the past two years we have built the InPreD-Norway national infrastructure for precision cancer diagnostics allowing stratification into PCM trials with a national molecular tumor board (publicly reimbursed, screened >300 in the first year), the IMPRESS-Norway national researcher-initiated PCM intervention trial (https://impress-norway.no), which opened for inclusion Q2 2021 and runs at all hospitals that treat cancer patients (22 sites, 17 hospital trusts; ), the INSIGHT/INCLUDE projects for research on control cohorts, use of real world evidence (RWE), health economics and reimbursement models, ethics, legal aspects and governance, and the CONNECT public-private partnership (https://www.connectnorway.org) for PCM implementation with 28 partners (16 pharma & biotech, 9 public and 3NGO partners) that provides a forum for policy discussions of reimbursement models and regulatory framework. Key learnings include how to build nation-wide initiatives, the importance of aligning top-down instructions with bottom-up approaches navigating politics and policies at multiple levels, that health economics and reimbursement models are necessary aspects and the need to understand different corporate cultures and create win-wins to make a public-private partnership work. Unique aspects of our experience include the nation-wide initiative, reimbursement of the molecular diagnostics w. population effect, drug reimbursement in our PCM trial and the public-private partnership model.
MoreTranslated text
Key words
cancer,medicine,norway
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined